Health Care & Life Sciences » Biotechnology | Idera Pharmaceuticals Inc.

Idera Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Idera Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Total Stock Market Index Fund
552,500
2.02%
0
0%
07/31/2018
iShares Russell 2000 ETF
400,124
1.47%
-213
0.01%
09/06/2018
Fidelity Select Biotechnology Portfolio
381,069
1.4%
0
0.04%
07/31/2018
Vanguard Extended Market Index Fund
316,457
1.17%
1
0.01%
07/31/2018
iShares Russell 2000 Growth ETF
185,988
0.68%
0
0.02%
09/06/2018
Fidelity Advisor Biotechnology Fund
106,602
0.39%
-2,513
0.04%
07/31/2018
Fidelity Spartan Extended Market Index Fund
102,953
0.38%
-1
0%
07/31/2018
Met Investors - JPMorgan Small Cap Value Portfolio
61,063
0.23%
-10,950
0.11%
03/31/2018
Royce Micro Cap Trust
58,061
0.21%
0
0.13%
06/30/2018
iShares Micro Cap ETF
51,139
0.19%
0
0.05%
09/06/2018

About Idera Pharmaceuticals

View Profile
Address
505 Eagleview Boulevard
Exton Pennsylvania 19341
United States
Employees -
Website http://www.iderapharma.com
Updated 07/08/2019
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. The firm uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. The company was founded by Paul C.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.